Analysis of Varying MicroRNAs as a Novel Biomarker for Early Diagnosis of Preeclampsia: A Scoping Systematic Review of the Observational Study

Muhammad Mikail Athif Zhafir Asyura, Maria Komariah, Shakira Amirah, Emir G. Faisal, Sidik Maulana, Hesti Platini, Tuti Pahria


Background: Preeclampsia (PE) is a pregnancy‑related syndrome with moderate mortality. Early diagnosis of the condition remains difficult, with the current diagnostic modalities being ineffective. The varying microRNAs (miRNAs) as a novel biomarker pose an alternative solution with their potential to be reviewed. Methods: This study follows the Preferred Reporting Item for Systematic Review and Meta‑Analysis Extended for Scoping Review (PRISMA‑ScR). PubMed/ MEDLINE, CENTRAL/Cochrane, ProQuest, Science Direct, and Wiley Online Library were used for this review. We only include observational studies. A critical appraisal was assessed in this study using QUADAS‑2. Results: We retrieved 30 observational studies fulfilling the set criteria. Data extracted were synthesized qualitatively based on miRNAs that are more prominent and their area‑under‑the‑curve (AUC) values. In total, 109 distinct dysregulated miRNAs were identified in comparison to healthy controls, with 10 of them (mir‑518b, mirR‑155, mirR‑155‑5p, miR‑122‑5p, miR‑517‑5p, miR‑520a‑5p, miR‑525‑5p, miR‑320a, miR‑210, and miR‑210‑3p) being identified in two or more studies. A brief look at the results shows that 49 miRNAs are downregulated and 74 miRNAs are upregulated, though the fold change of the dysregulation in all studies is not available due to some studies opting for a visual representation of the differences using whisker plots, bar charts, and heat map diagrams to visualize the difference from the reference control. Conclusions: This study has analyzed the potential of varying miRNAs as potential diagnostic biomarkers and how they might be used in the future. Despite this, potent miRNAs identified should be more emphasized in future research to determine their applicability and connection with the pathogenesis.


Biomarkers; early diagnosis; microRNAs; preeclampsia; pregnancy

Full Text:



Gathiram P, Moodley J. Pre‑eclampsia: Its pathogenesis and

pathophysiolgy. Cardiovasc J Afr 2016;27:71–8.

Poon LC, Shennan A, Hyett JA, Kapur A, Hadar E, Divakar H,

et al. The International Federation of Gynecology and

Obstetrics (FIGO) initiative on pre‑eclampsia: A pragmatic guide

for first‑trimester screening and prevention. Int J Gynecol Obstet


Hypertension in pregnancy. Report of the American College of

Obstetricians and Gynecologists’ Task Force on Hypertension in

Pregnancy. Obstet Gynecol 2013;122:1122–31.

Staff AC, Benton SJ, Von Dadelszen P, Roberts JM,

Taylor RN, Powers RW, et al. Redefining preeclampsia using

placenta‑derived biomarkers. Hypertension 2013;61:932–42.

Marín R, Chiarello DI, Abad C, Rojas D, Toledo F, Sobrevia L.

Oxidative stress and mitochondrial dysfunction in early‑onset

and late‑onset preeclampsia. Biochim Biophys Acta Mol Basis

Dis 2020;1866:165961.

Jiang R, Wang T, Zhou F, Yao Y, He J, Xu D.

Bioinformatics‑based identification of miRNA‑, lncRNA‑, and

mRNA‑associated ceRNA networks and potential biomarkers for

preeclampsia. Medicine (Baltimore) 2020;99:e22985.

Brown MA, Magee LA, Kenny LC, Karumanchi SA,

McCarthy FP, Saito S, et al. Hypertensive disorders of

pregnancy: ISSHP classification, diagnosis, and management

recommendations for international practice. Hypertens (Dallas,

Tex 1979) 2018;72:24–43.

Zhao G, Zhou X, Chen S, Miao H, Fan H, Wang Z, et al.

Differential expression of microRNAs in decidua‑derived

mesenchymal stem cells from patients with pre‑eclampsia.

J Biomed Sci 2014;21:1–12.

Sheridan R, Belludi C, Khoury J, Stanek J, Handwerger S.

FOXO1 expression in villous trophoblast of preeclampsia

and fetal growth restriction placentas. Histol Histopathol


Yin Y, Liu M, Yu H, Zhang J, Zhou R. Circulating microRNAs

as biomarkers for diagnosis and prediction of preeclampsia:

A systematic review and meta‑analysis. Eur J Obstet Gynecol

Reprod Biol 2020;253:121–32.

Tricco AC, Lillie E, Zarin W, O’Brien KK, Colquhoun H,

Levac D, et al. PRISMA extension for scoping

reviews (PRISMA‑ScR): Checklist and explanation. Ann Intern

Med 2018;169:467–73.

Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ,

Reitsma JB, et al. QUADAS‑2: A revised tool for the quality

assessment of diagnostic accuracy studies. Ann Intern Med


Dayan N, Schlosser K, Stewart DJ, Delles C, Kaur A, Pilote L.

Circulating MicroRNAs implicate multiple atherogenic

abnormalities in the long‑term cardiovascular sequelae of

preeclampsia. Am J Hypertens 2018;31:1093–7.

Hromadnikova I, Kotlabova K, Ivankova K, Krofta L. First

trimester screening of circulating C19MC microRNAs and the

evaluation of their potential to predict the onset of preeclampsia

and IUGR. PLoS One 2017;12:1–17.

Li Q, Long A, Jiang L, Cai L, Xie LI, Gu J, et al. Quantification

of preeclampsia‑related microRNAs in maternal serum. Biomed

Rep 2015;3:792–6.

Jiang F, Li J, Wu G, Miao Z, Lu L, Ren G, et al. Upregulation

of microRNA‑335 and microRNA‑584 contributes to the

pathogenesis of severe preeclampsia through downregulation of

endothelial nitric oxide synthase. Mol Med Rep 2015;12:5383–90.

Vashukova ES, Glotov AS, Fedotov PV, Efimova OA, Pakin VS,

Mozgovaya EV, et al. Placental microRNA expression in

pregnancies complicated by superimposed pre‑eclampsia on

chronic hypertension. Mol Med Rep 2016;14:22–32.

Zhong Y, Zhu F, Ding Y. Differential microRNA expression

profile in the plasma of preeclampsia and normal pregnancies.

Exp Ther Med 2019;18:826–32.

Li Q, Han Y, Xu P, Yin L, Si Y, Zhang C, et al. Elevated

microRNA‑125b inhibits cytotrophoblast invasion and impairs

endothelial cell function in preeclampsia. Cell Death Discov


Kim S, Park M, Kim J‑Y, Kim T, Hwang JY, Ha K‑S, et al.

Circulating miRNAs associated with dysregulated vascular and

trophoblast function as target‑based diagnostic biomarkers for

preeclampsia. Cells 2020;9:2003.

Xie N, Jia Z, Li L. miR‑320a upregulation contributes to the

development of preeclampsia by inhibiting the growth and

invasion of trophoblast cells by targeting interleukin 4. Mol Med

Rep 2019;20:3256–64.

Zhu L, Liu Z. Serum from patients with hypertension promotes

endothelial dysfunction to induce trophoblast invasion through

the miR‑27b‑3p/ATPase plasma membrane Ca(2+) transporting 1

axis. Mol Med Rep 2021;23:319.

Demirer S, Hocaoglu M, Turgut A, Karateke A,

Komurcu‑Bayrak E. Expression profiles of candidate microRNAs

in the peripheral blood leukocytes of patients with early‑ and

late‑onset preeclampsia versus normal pregnancies. Pregnancy

Hypertens 2020;19:239–45.

Liu E, Zhou Y, Li J, Zhang D. MicroRNA‑491‑5p inhibits

trophoblast cell migration and invasion through targeting

matrix metalloproteinase‑9 in preeclampsia. Mol Med Rep


Tang Q, Gui J, Wu X, Wu W. Downregulation of miR‑424 in

placenta is associated with severe preeclampsia. Pregnancy

Hypertens 2019;17:109–12.

Jelena M, Sopić M, Joksić I, Zmrzljak UP, Karadžov‑Orlić N,

Košir R, et al. Placenta‑specific plasma miR518b is a potential

biomarker for preeclampsia. Clin Biochem 2020;79:28–33.

Youssef HMG, Marei ES. Association of MicroRNA‑210 and

MicroRNA‑155 with severity of preeclampsia. Pregnancy

Hypertens 2019;17:49–53.

Niu Z‑R, Han T, Sun X‑L, Luan L‑X, Gou W‑L, Zhu X‑M.

MicroRNA‑30a‑3p is overexpressed in the placentas of patients

with preeclampsia and affects trophoblast invasion and apoptosis

by its effects on IGF‑1. Am J Obstet Gynecol 2018;218:249.e1‑12.

Martinez‑Fierro ML, Carrillo‑Arriaga JG, Luevano M,

Lugo‑Trampe A, Delgado‑Enciso I, Rodriguez‑Sanchez IP, et al.

Serum levels of miR‑628‑3p and miR‑628‑5p during the early

pregnancy are increased in women who subsequently develop

preeclampsia. Pregnancy Hypertens 2019;16:120–5.

Timofeeva AV, Gusar VA, Kan NE, Prozorovskaya KN,

Karapetyan AO, Bayev OR, et al. Identification of potential early

biomarkers of preeclampsia. Placenta 2018;61:61–71.

Nejad RMA, Saeidi K, Gharbi S, Salari Z, Saleh‑Gohari N.

Quantification of circulating miR‑517c‑3p and miR‑210‑3p

levels in preeclampsia. Pregnancy Hypertens 2019;16:75–8.

Dong K, Zhang X, Ma L, Gao N, Tang H, Jian F, et al.

Downregulations of circulating miR‑31 and miR‑21 are associated

with preeclampsia. Pregnancy Hypertens 2019;17:59–63.

Li H, Ouyang Y, Sadovsky E, Parks WT, Chu T, Sadovsky Y.

Unique microRNA signals in plasma exosomes from pregnancies

complicated by preeclampsia. Hypertension 2020;75:762–71.

Yoffe L, Gilam A, Yaron O, Polsky A, Farberov L, Syngelaki A,

et al. Early detection of preeclampsia using circulating small

non‑coding RNA. Sci Rep 2018;8:3401.

Hromadnikova I, Dvorakova L, Kotlabova K, Krofta L. The

prediction of gestational hypertension, preeclampsia and fetal

growth restriction via the first trimester screening of plasma

exosomal C19MC microRNAs. Int J Mol Sci 2019;20:2972.

Xueya Z, Yamei L, Sha C, Dan C, Hong S, Xingyu Y, et al.

Exosomal encapsulation of miR‑125a‑5p inhibited trophoblast cell

migration and proliferation by regulating the expression of VEGFA

in preeclampsia. Biochem Biophys Res Commun 2020;525:646–53.

Yang H‑L, Zhang H‑Z, Meng F‑R, Han S‑Y, Zhang M.

Differential expression of microRNA‑411 and 376c is associated

with hypertension in pregnancy. Braz J Med Biol 2019;52:e7546.

doi: 10.1590/1414‑431X20197546.

Yuan Y, Wang X, Sun Q, Dai X, Cai Y. MicroRNA‑16 is

involved in the pathogenesis of pre‑eclampsia via regulation of

Notch2. J Cell Physiol 2020;235:4530–44.

Salomon C, Guanzon D, Scholz‑Romero K, Longo S, Correa P,

Illanes SE, et al. Placental exosomes as early biomarker of

preeclampsia: Potential role of exosomal MicroRNAs across

gestation. J Clin Endocrinol Metab 2017;102:3182–94.

Awamleh Z, Gloor GB, Han VKM. Placental microRNAs in

pregnancies with early onset intrauterine growth restriction

and preeclampsia: Potential impact on gene expression and

pathophysiology. BMC Med Genomics 2019;12:91.

Zhang H, Xue L, Lv Y, Yu X, Zheng Y, Miao Z, et al. Integrated

microarray analysis of key genes and a miRNA‑mRNA

regulatory network of early‑onset preeclampsia. Mol Med Rep


Jairajpuri DS, Malalla ZH, Mahmood N, Almawi WY.

Circulating microRNA expression as predictor of preeclampsia

and its severity. Gene 2017;627:543–8.

Zakiyah N, Postma MJ, Baker PN, van Asselt ADI. Pre‑eclampsia

diagnosis and treatment options: A review of published economic

assessments. Pharmacoeconomics 2015;33:1069–82.

Magee LA, Pels A, Helewa M, Rey E, von Dadelszen P.

Diagnosis, evaluation, and management of the hypertensive

disorders of pregnancy. Pregnancy Hypertens 2014;4:105–45.

Menzies J, Magee LA, Macnab YC, Ansermino JM, Li J,

Douglas MJ, et al. Current CHS and NHBPEP criteria for severe

preeclampsia do not uniformly predict adverse maternal or

perinatal outcomes. Hypertens Pregnancy 2007;26:447–62.

Karumanchi SA, Epstein FH. Placental ischemia and

soluble fms‑like tyrosine kinase 1: Cause or consequence of

preeclampsia? Kidney Int 2007;71:959‑61.

Fox R, Kitt J, Leeson P, Aye CYL, Lewandowski AJ.

Preeclampsia: Risk factors, diagnosis, management, and the

cardiovascular impact on the offspring. J Clin Med 2019;8:1625.

Brunelli VB, Prefumo F. Quality of first trimester risk prediction

models for pre‑eclampsia: A systematic review. BJOG


Contro E, Bernabini D, Farina A. Cell‑free fetal DNA for the

prediction of pre‑eclampsia at the first and second trimesters:

A systematic review and meta‑analysis. Mol Diagn Ther


Beermann J, Piccoli M‑T, Viereck J, Thum T. Non‑coding RNAs

in development and disease: Background, mechanisms, and

therapeutic approaches. Physiol Rev 2016;96:1297–325.

Enquobahrie DA, Abetew DF, Sorensen TK, Willoughby D,

Chidambaram K, Williams MA. Placental microRNA expression

in pregnancies complicated by preeclampsia. Am J Obstet

Gynecol 2011;204:178.e12‑21.

Wu L, Zhou H, Lin H, Qi J, Zhu C, Gao Z, et al. Circulating

microRNAs are elevated in plasma from severe preeclamptic

pregnancies. Reproduction 2012;143:389–97.

Luo L, Ye G, Nadeem L, Fu G, Yang BB, Honarparvar E, et al.

MicroRNA‑378a‑5p promotes trophoblast cell survival, migration

and invasion by targeting Nodal. J Cell Sci 2012;125:3124–32.

Gunel T, Hosseini MK, Gumusoglu E, Kisakesen HI, Benian A,

Aydinli K. Expression profiling of maternal plasma and

placenta microRNAs in preeclamptic pregnancies by microarray

technology. Placenta 2017;52:77–85.

Hornakova A, Kolkova Z, Holubekova V, Loderer D,

Lasabova Z, Biringer K, et al. Diagnostic potential of

MicroRNAs as biomarkers in the detection of preeclampsia.

Genet Test Mol Biomarkers 2020;24:321–7.

Mitchell MD, Peiris HN, Kobayashi M, Koh YQ, Duncombe G,

Illanes SE, et al. Placental exosomes in normal and complicated

pregnancy. Am J Obstet Gynecol 2015;213 (4 Suppl):S173‑81.

Peltier HJ, Latham GJ. Normalization of microRNA expression

levels in quantitative RT‑PCR assays: Identification of suitable

reference RNA targets in normal and cancerous human solid

tissues. RNA 2008;14:844–52.